Alnylam Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Madrid, Spain.
2 reports, 2 independent
Updated Aug 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Madrid, Spain.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
European Society of Cardiology
non-profit knowledge-based professional association
Related events
- Tenax Therapeutics presented findings and announced results at the European Society of Cardiology Congress 2026.
- BridgeBio presented data at the annual ESC Congress in 2026, with Marianna Fontana affiliated with UCL.
- Research addressing limitations in ESC guidelines was presented, involving Aalborg University and Aamir Mahmood.
- Trial results regarding HeartFlow Inc. were presented at the ESC Congress, focusing on how AI technology supports the guidelines of the American College of Cardiology.
- GE Healthcare unveiled new cardiovascular ultrasound systems at the ESC Congress in Munich.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- Business WireAlnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - Company to Webcast Investor Event on Augus